– Product Launch Planned for September; ABRAXANE Now Approved in 40 Countries –
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE® IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment...
Released: 7/22/2010 10:00 AM EDT Source: Case Western Reserve University
Newswise — Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult. Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early...
The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.
Oral cancer is an under-treated and poorly understood disease, says Xiaofeng "Charles" Zhou, assistant professor in the UIC Center for Molecular Biology of Oral Diseases and lead researcher of the study.
Pharma market research giant IMS Health has expanded its IMS Oncology Analyzer market measurement tool to provide anonymized patient-level information across several additional cities in China.
IMS Health was recently acquired by investment firms TPG Capital and the Canada Pension Plan Investment Board (CPPIB), for $5.2bn.
Its IMS Oncology Analyzer is an evidence-based, quant market research tool used to measure life cycle management strategies,...
Circulating aberrant cells increase as non-small cell lung cancer progresses
HOUSTON -- A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by scientists at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research.
